2015•Journal of the National Comprehensive Cancer NetworkOpen access
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015
Andrew David Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, Charalambos Babis Andreadis, Nancy L. Bartlett, John C. Byrd, Myron Stefan Czuczman, Luis Fayad, Richard I. Fisher, Martha Jane Glenn, Thomas Matthew Habermann, Nancy L. Harris, Richard T. Hoppe, Steven M. Horwitz, Chris R. Kelsey, Youn H. Kim, Susan Krivacic, Ann Steward LaCasce, Auayporn P. Nademanee, Pierluigi Porcu, Oliver W. Press, Rachel A Rabinovitch, Nishitha M Reddy, Erin Gourley Reid, Ayman A Saad, Lubomir Sokol, Lode J. Swinnen, Christina I. Tsien, Julie Marie Vose, Lynn D. Wilson, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer, Hema M. Sundar
Open full text 78 citations
Abstract
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.
Open-access reader